March 28 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:
FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVT
MILESTONE PHARMACEUTICALS INC - FDA RAISES NO CONCERNS ON ETRIPAMIL CLINICAL SAFETY OR EFFICACY
MILESTONE PHARMACEUTICALS INC - CRL FOCUSED ON CMC; NO CLINICAL ISSUES RELATING TO ETRIPAMIL RAISED
MILESTONE PHARMACEUTICALS INC - COMPANY TO SUBMIT ADDITIONAL INFO ON NITROSAMINE IMPURITIES
MILESTONE PHARMACEUTICALS INC - INSPECTION REQUIRED AT FACILITY PERFORMING ETRIPAMIL RELEASE TESTING
Source text: ID:nGNXZV9tl
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。